Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients

Paolo Milani, MDPhD, Nelson Leung, MD, Efstathios Kastritis, MD, Stefan Schönland, MD, Ute Hegenbart, MD, Frank Bridoux, MD, Florent Joly, MD, Sascha A Tuchman, MD, Victor Jimenez-Zepeda, MD, Sriram Ravichandran, MBBS, MRCP, FRCPath, Holly Lee, MD, Tamara Berno, MD, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141662

Published: 2020

Journal Articles

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey

Paolo Milani, MDPhD, Vaishali Sanchorawala, MD, Ramon Lecumberri, MD PhD, Sunil Saith, MD, Mathew S. Maurer, MD, M. Teresa Cibeira, MD PhD, Giampaolo Merlini, MD, Stefan Schönland, MD, Giovanni Palladini, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-141569

Published: 2020

Journal Articles

Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Ashutosh D. Wechalekar, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD, Raymond L. Comenzo, MD, Arnaud Jaccard, MD PhD, NamPhuong Tran, MD, Huiling Pei, PhD, Sandra Y. Vasey, MSc, Brenda Tromp, MSc, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Efstathios Kastritis, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140514

Published: 2020

Journal Articles

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Giovanni Palladini, MD PhD, Stefan Schönland, MD, Giampaolo Merlini, MD, Paolo Milani, MDPhD, Arnaud Jaccard, MD PhD, Frank Bridoux, MD PhD, Wilfried Roeloffzen, MD PhD, M. Teresa Cibeira, MD PhD, Hermine Agis, MD, Monique C. Minnema, MD PhD, Rui Bergantim, MD, Roman Hajek, MD PhD, Cristina João, MD PhD MSc, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM, Pieter Sonneveld, MD PhD, Efstathios Kastritis, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140708

Published: 2020

Journal Articles

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood (2020) 136 (Supplement 1): 48–50.

https://doi.org/10.1182/blood-2020-137582

Published: 2020

Journal Articles

The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis

Giovanni Palladini, MD PhD, Paolo Milani, MDPhD, Simone Celant, Valentina Summa, MD, Giovanni Affronti, Pier Paolo Olimpieri, PhD, Sandra Petraglia, MD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Giampaolo Merlini, MD, Pierluigi Russo, MD PhD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-141563

Published: 2020

Journal Articles

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 37–40.

https://doi.org/10.1182/blood-2020-139438

Published: 2020

Journal Articles

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Paolo Milani, MD PhD, Francesca Fazio, MD, Marco Basset, MD, Tamara Berno, MD, Alessandra Larocca, Andrea Foli, MD, Marcello Riva, MD, Stefania Oliva, Jessica Ripepi, Mario Nuvolone, MD PhD, Maria Teresa Petrucci, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1860.

https://doi.org/10.1182/blood-2019-130675

Published: 2019

Journal Articles

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Eftathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, MD, Giampaolo Merlini, MD, Pieter Sonneveld, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1868.

https://doi.org/10.1182/blood-2019-126524

Published: 2019

Journal Articles

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Paolo Milani, MD PhD, Marco Basset, MD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1901.

https://doi.org/10.1182/blood-2019-130378

Published: 2019

Journal Articles

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Marco Basset, MD, Paolo Milani, MD PhD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 3312.

https://doi.org/10.1182/blood-2019-130364

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Paolo Milani, MD, Faye Sharpley, Stefan Schönland, Marco Basset, MD, Shameem Mahmood, Christoph Kimmich, Andrea Foli, MD, Sajitha Sachchithanantham, Giampaolo Merlini, MD, Ashutosh D. Wechalekar, Giovanni Palladini, MD PhD, Ute Hegenbart

Blood (2018) 132 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2018-99-118034

Published: 2018

Journal Articles

Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response

Giovanni Palladini, MD PhD, Margherita Massa, Marco Basset, MD, Francesca Russo, MD, Paolo Milani, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2016) 128 (22): 3261.

https://doi.org/10.1182/blood.V128.22.3261.3261

Published: 2016

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2016) 128 (22): 646.

https://doi.org/10.1182/blood.V128.22.646.646

Published: 2016

Journal Articles

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Efstathios Kastritis, MD, Giampaolo Merlini, MD, Ioannis Papassotiriou, PhD, Paolo Milani, MD, Evangelos Terpos, Marco Basset, MD, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostoloakou, Maria Roussou, Maria Gavriatopoulou, Despina Fotiou, Dimitrios Ziogas, Constantinos Pamboucas, Elektra Papadopoulou, Meletios A Dimopoulos, Giovanni Palladini, MD PhD

Blood (2016) 128 (22): 648.

https://doi.org/10.1182/blood.V128.22.648.648

Published: 2016

Journal Articles

Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years

Maria Gavriatopoulou, Ramon Garcia-Sanz, Efstathios Kastritis, MD, Pierre Morel, Marie-Christine Kyrtsonis, MD PhD, Evridiki Michalis, Zafeirios Kartasis, Xavier Leleu, Giovanni Palladini, MD PhD, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, MD, Pieter Sonneveld, Meletios A Dimopoulos

Blood (2016) 128 (22): 2957.

https://doi.org/10.1182/blood.V128.22.2957.2957

Published: 2016

Journal Articles

Patterns of Relapse after Upfront Therapy in AL Amyloidosis

Paolo Milani, MD, Marco Basset, MD, Francesca Russo, MD, Andrea Foli, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD

Blood (2016) 128 (22): 2140.

https://doi.org/10.1182/blood.V128.22.2140.2140

Published: 2016

Journal Articles

The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis

Sandy W. Wong, MD, Giovanni Palladini, MD PhD, Ute Hegenbart, MD, Heather Landau, MD, Melissa Warner, BS, Arnaud Jaccard, MD PhD, Herve Avet-Loiseau, Timon Hansen, MD, Joan Bladé, MD, María Teresa Cibeira, MD, Efstathios Kastritis, MD, Stefan Schönland, MD, Raymond L. Comenzo, MD

Blood (2015) 126 (23): 3049.

https://doi.org/10.1182/blood.V126.23.3049.3049

Published: 2015

Journal Articles

Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome

Paolo Milani, MD, Andrea Foli, MD, Marco Basset, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD

Blood (2015) 126 (23): 1773.

https://doi.org/10.1182/blood.V126.23.1773.1773

Published: 2015

NARROW

Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey

Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years

Patterns of Relapse after Upfront Therapy in AL Amyloidosis

The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis

Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only